Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income: 2017-2025

Historic Other Non Operating Income for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to -$10,000.

  • Akebia Therapeutics' Other Non Operating Income rose 41.18% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $158,000, marking a year-over-year increase of 85.88%. This contributed to the annual value of -$517,000 for FY2024, which is 158.29% down from last year.
  • Akebia Therapeutics' Other Non Operating Income amounted to -$10,000 in Q3 2025, which was up 64.29% from -$28,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Non Operating Income registered a high of $1.3 million during Q2 2021, and its lowest value of -$517,000 during Q1 2024.
  • Moreover, its 3-year median value for Other Non Operating Income was -$13,500 (2023), whereas its average is $48,900.
  • In the last 5 years, Akebia Therapeutics' Other Non Operating Income surged by 604.35% in 2022 and then tumbled by 290.00% in 2024.
  • Akebia Therapeutics' Other Non Operating Income (MRQ) stood at $560,000 in 2021, then decreased by 22.50% to $434,000 in 2022, then skyrocketed by 51.61% to $658,000 in 2023, then crashed by 102.58% to -$17,000 in 2024, then soared by 41.18% to -$10,000 in 2025.
  • Its Other Non Operating Income was -$10,000 in Q3 2025, compared to -$28,000 in Q2 2025 and $213,000 in Q1 2025.